Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Stock Report: Ascendis Pharma A/S Sponsored ADR (ASND) Report Updated: Dec 26, 2018 | Print This Page

Get more stock ratings by Louis Navellier

Ascendis Pharma A/S Sponsored ADR (ASND)

Rating: Strong Buy Volatility: Conservative
Total Grade: A Industry: Biotechnology

Stock Analysis

Rating: Monthly View

May June July August September October November December January February March April

Rating: Weekly View

This Week: A down no change
Last Week: A same no change
Two Weeks Ago: A up no change
service keys

Ascendis Pharma A/S Sponsored ADR© quotemedia

Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil that is in Phase I study for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi and Genentech. The company was founded in 2006 and is headquartered in Hellerup, Denmark.